bluuebunny/crossref_metadata_2025_split huggingface dataset:
‘Suction split’ as a routine method to differentiate epidermolysis bullosa acquisita from bullous pemphigoid1
Authors: Feliciani Claudio , Di Muzio Marcello , Pour Saman Mohammad , Allegretti Tiziana , Amerio Paolo , Toto Paola , Coscione Giulia , Proietto Gianluca , Amerio Pierluigi 
Published: September 2006

AbstractBackground and DesignEpidermolysis bullosa acquisita (EBA) and bullous pemphigoid (BP) are diseases with similar clinical, histological, and immunofluorescent findings. Diagnosis requires the use of immunoelectron microscopy, immuno‐precipitation or immunoblotting, but in recent years the differential diagnosis has been based on a cheaper technique named salt split skin. This study demonstrates that with a suction blister the fracture is at the same level as that obtained with the sodium split method and that it is also faster and cheaper. Suction blisters on normal skin and autoimmune perilesional bullous lesions, obtained with a hand vacuum pump, were studied by direct immunofluorescence and electron microscopy to evaluate the level of the split on normal suction split skin. Normal human split skin was also used as a substrate for an indirect immunofluorescent study using sera of patients with BP (68 sera), EBA (10 sera) and cicatricial pemphigoid (CP) (16 sera). Direct immunofluorescent examination was also done on perilesional skin after artificial separation obtained with a hand‐vacuum pump in patients with the same diseases listed above (32 BP, 11 CP, 6 EBA).ResultsOn normal human skin split by suction or sodium chloride (NaCl; 1 mol/1) direct immunofluorescence and electron microscopy demonstrated that the split is at the lamina lucida level. Indirect immunofluorescent study of both normal human skin and perilesional skin split using suction as a substrate showed IgG deposits localized on the floor of the suction blister in all cases of EBA, whereas in over 88% of cases of BP and in over 62% of CP the IgG were localized on the roof. Similar results were obtained with direct immunofluorescence in perilesional skin.Conclusions‘Suction split’ represents a simple technique to differentiate EBA from BP. This method provides final response in a few hours compared to at least 1–2 days with the sodium split method. Furthermore, the suction split method is cheaper and the tissue can be re‐utilized for molecular biology and immunohistochemical studies.
Mycosis fungoides with involvement of the oral cavity
Authors: Harman Mehmet , Akdeniz Sedat , Arslan Adem , Aöyoĝlu Sadik 
Published: September 2006

AbstractMycosis fungoides rarely involves the oral cavity. To our knowledge only 29 cases of oral cutaneous T‐cell lymphoma have been described up to 1994. This report presents a case of mycosis fungoides with involvement of the oral cavity in a 57‐year‐old man who died from septicemia 7 months after the onset of oral involvement.
Fatal cytophagic histiocytic panniculitis after a short response to cyclosporine
Authors: Guitart Joan , Sethi Ruchi , Gordon Kenneth 
Published: September 2006

AbstractCytophagic histiocytic panniculitis (CHP) is a disorder characterized by a histiocytic infiltrate in the subcutaneous adipose tissue which often extends to involve systemic organs. Fever, pancytopenia, hepatosplenomegaly, mucosal ulcers and serositis are common systemic symptoms. Although remissions have been reported, the disease tends to follow a chronic course often complicated by terminal hemorrhagic diathesis and death. Several reports in the recent literature have suggested that cyclosporine is the treatment of choice in CHP. We report the first case of cyclosporine treatment failure in CPH. Despite an initial response to treatment and persistent resolution of cutaneous lesions, the internal disease progressed resulting in the patient's death. Therefore the evolution of skin lesions and signs of systemic involvement may not be an accurate assessment of disease activity in patients with CHP being treated with cyclosporine.
Medium dose isotretinoin for the treatment of acne
Authors: Hermes B. , Praetel C. , Henz B.M. 
Published: September 2006

AbstractBackgroundAlthough the efficacy of isotretinoin in the treatment of acne is unquestioned, improvement of patient tolerance and acceptance of the drug are desirable. Furthermore, no data on acne‐induced scarring during isotretinoin treatment are available.AimIn the present study, we have evaluated the efficacy and tolerability of an initial stepwise incremental (n= 83) or an initial high dose (n= 11) and a subsequent medium maintenance dosing of isotretinoin in outpatients treated for acne over a 7 year period.MethodsNinety‐four patients with moderate to severe acne were treated for a mean duration of 8.3 months, at a mean daily dose of 31.4 mg. Follow‐up and final evaluation were done during outpatient visits and with a standardized patient questionnaire.ResultsResponse to treatment was very good in 62.8% and good in 31.9% of patients, with only one treatment failure. Of the patients, 21.3% required retreatment after a mean interval of 7.7 months. Four patients refused or dropped out from treatment, 27% noted initial mild worsening of their acne, and none experienced severe adverse effects. Scars were present in 89.4% of patients, with improvement occurring in 67.9% during treatment.ConclusionThe altogether good to excellent clinical response of acne lesions and acne scars, with a low side effect profile, warrants further study of this simple, modified treatment regimen in patients with acne and acne‐induced scarring.
Disseminated skin infection due to Mycobacterium fortuitum in an immunocompetent patient
Authors: Salvador J.F. Silvestre , Betlloch M.I. , Alfonso R. , Ramón R.L. , Morell A.M. , Navas J. 
Published: September 2006

AbstractSkin infections caused by atypical rapid‐growing mycobacteria, which used considered to be unusual, have become more frequent, especially in immunodepressed patients. Clinical cutaneous disease with these pathogens seems to follow two patterns: in the immunocompetent host, a traumatic injury is followed by the development of localized abscess formation; but in the immunocompromised individual there is no history of trauma and the patient presents with multiple subcutaneous nodular lesions. We describe a rare case of an immunocompetent young woman with disseminated skin infection due to Mycobacterium fortuitum. We emphasize the diagnostic and therapeutic problems associated with such infections.
Depot sulfonamid associated linear IgA bullous dermatosis with erythema multiforme‐like clinical features
Authors: Tonev S. , Vasileva S. , Kadurina M. 
Published: September 2006

AbstractA case of erythema multiforme‐like reaction, following therapy with sulfadimethoxynum is reported in a 19‐year‐old male patient. Histological examination demonstrated a subepidermal bulla and direct immunofluorescence revealed linear deposition of IgA at the dermoepidermal junction. These observations illustrate that linear IgA bullous dermatosis can mimic the clinical features of erythema multiforme and suggest the possibility of drug‐induced pathogenesis.
Efficacy of cyclosporine plus etretinate in the treatment of erythrodermie psoriasis (three case reports)
Authors: Kokelj Franco , Plozzer Carmela , Torsello Pierpaolo , Trevisan Giusto 
Published: September 2006

AbstractBackgroundAssociation of different treatments are often used in erythrodermic psoriasis in order to increase the effectiveness and decrease the incidence of side effects due to single drugs.Materials and methodsThree in‐patients affected by erythrodermic psoriasis, not responding to cyclosporine, (two patients) and etretinate, (one patient), were treated with the association cyclosporine plus etretinate.ResultsClinical response was prompt to the combined therapy. The two drugs were tapering off gradually over 6 months; the patients maintained the remission for prolonged period.ConclusionsCombined cyclosporine‐etretinate therapy may be considered as an effective and well tolerated treatment of erythrodermic psoriasis in patients not responding to monotherapy regimen.
Transdermal absorption of topical anti‐acne agents in man; review of clinical pharmacokinetic data
Authors: van Hoogdalem E.J. 
Published: September 2006

AbstractBackgroundApart from oral drug treatment, drug therapy in acne vulgaris comprises topical treatment with agents with a primarily keratolytic action (e.g. tretinoin and benzoylperoxide), and with antibiotics (clindamycin, erythromycin, and erythromycin‐zinc complex). The acne grade in the particular patient usually determines the selection of the preferred route of administration, viz. topical or oral, or a combination of both, and topical treatment is usually preferred in mild to moderate acne. The fact that a topically applied compound may also become systemically available to a quantifiable extent, is not generally considered.AimThe present paper reviews the clinical data on transdermal uptake of anti‐acne agents in man, also with respect to their relevance for daily clinical practice.OutcomeThe majority of published data on transdermal penetration of topical anti‐acne agents focuses on the retinoid tretinoin, and on the antimicrobial agent clindamycin. This interest emerges from the fact that these agents have been associated with embryotoxicity/teratogenicity, and pseudomembranous colitis, respectively. For both compounds the extent of systemic availability after topical application is low, viz. 5–7% and 8%, respectively, at its highest. The height and variability in endogenous retinoid levels is very likely to outweigh any contribution of exogenously applied tretinoin, but a full consensus on the safe use of topical tretinoin in pregnancy is still lacking. With respect to clindamycin, the suggested association between its topical use and the occurrence of pseudomembranous colitis appears not to be of clinical relevance. In order to reduce systemic exposure to clindamycin as much as possible, topical application of clindamycin phosphate is to be preferred over clindamycin hydrochloride salt. Regarding other topical anti‐acne agents, it has been suggested that topical zinc‐erythromycin is to be preferred over erythromycin, both from clinical efficacy and safety viewpoints. With respect to the currently used compounds like benzoylperoxide, azelaic acid, and adapalene, available clinical pharmacokinetic data are scarce, and significant safety concerns did not emerge as yet.ConclusionThe limited transdermal uptake of topical anti‐acne agents underpins their safe use in daily clinical practice. With respect to topical retinoids, formal consensus is lacking regarding their use in pregnancy.
Clinical efficacy of Velac®, a new tretinoin and clindamycin phosphate gel in acne vulgaris
Authors: Cambazard F. 
Published: September 2006

AbstractVelac®, a new gel formulation containing both tretinoin (0.025%) and clindamycin phosphate (1.2%), is effective in acne vulgaris using a once daily application. The single formulation enhances compliance in young patients and improves the therapeutic results. Treatment with Velac was found to be more effective than tretinoin alone in inflamed lesions and at least comparable in open and closed comedones. In two of the three studies the overall acne severity grade was significantly more reduced when compared with tretinoin. Velac is also more effective than clindamycin alone in the treatment of the non‐inflamed lesions. In the two multicentre studies the reduction of the overall acne severity grade was also more favourable for the new gel formulation. A more rapid response occurred with Velac than with either component used (clindamycin or tretinoin) alone.
Skin diseases associated with hepatitis C virus infection
Authors: Hadziyannis Stephanos J. 
Published: September 2006

AbstractHepatitis C virus (HCV) is a bloodborne agent transmitted by apparent and inapparent parenteral procedures representing a frequent cause of liver disease world‐wide. Both acute and chronic HCV infection may affect the liver as well as various non‐hepatic tissues. Numerous extrahepatic disorders have been recognised in association with HCV infection among which dermatological diseases occupy a central part. Cutaneous necrotising vasculitis, mixed cryoglobulinemia, porphyria cutanea tarda and lichen planus are the major skin diseases frequently associated with HCV infection, but other skin disorders, such as Adamantiadis‐BehQet syndrome, erythema multiforme and nodosum, malacoplakia, urticaria and pruritus, may also be linked to hepatitis C. Further studies are necessary to establish or refute an aetiopathogenetic role of HCV in these conditions. Skin manifestations are also part of the clinical picture of other extrahepatic disorders associated with HCV infection, such as thyroid dysfunction and HCV‐related thrombocytopenia. The response to interferon alpha (a‐IFN) therapy in skin diseases is unpredictable with some patients ameliorating, others remaining stationary and others deteriorating.
Low‐dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients
Authors: Gibson G.E. , O'Grady A. , Kay E.W. , Murphy G.M. 
Published: September 2006

AbstractBackground Renal transplant recipients have an increased incidence of skin cancers, which may be multiple and aggressive.Objectives The purpose of this study was to examine the chemoprophylactic effects of low‐dose etretinate (0.3 mg/kg/day) on skin cancer development in renal transplant recipients and to monitor retinoid toxic effects at this dose.Methods All skin lesions were counted and photographed prior to therapy with etretinate. Patients were assessed at monthly intervals for new skin lesions and for retinoid toxicity.Results Eleven renal transplant recipients participated. There was a significant reduction in the number of skin cancers which occurred during etretinate therapy compared with pre‐treatment for 3 and 6 months of treatment, and a trend towards fewer skin cancers in the 12 and 18 month treatment periods. Side‐effects were well‐tolerated and no significant biochemical effects were observed.Conclusion Low dose etretinate is safe, well‐tolerated and partially effective in chemoprophylaxis of skin cancer in renal transplant recipients.
An unusual case of primary systemic amyloidosis
Authors: Ambrosone L. , Mansi L. , Salvatore T. , Marino F. , Orabona P. , Rambaldi A. , Rambaldi P.F. , Rambaldi M. 
Published: September 2006

AbstractHere we report an unusual case of primary systemic amyloidosis. The cutaneous lesions were polymorphic and included involvement of both external auditory canals. The visceral involvement was covert. Mapping of amyloid deposits was performed using scintigraphy with technetium‐99m (V) dimercaptosuccinic acid ([99mTc (V)] DMSA). Therapy with melpha‐lan, prednisone and colchicine resulted in considerable improvement.
Linear IgA bullous dermatosis induced by piroxicam1
Authors: Camilleri Michael , Pace Joseph L. 
Published: September 2006

AbstractLinear IgA bullous dermatosis (LABD) is an acquired, autoimmune, heterogeneous subepidermal blistering disorder usually idiopathic in nature, but in recent years a variety of drugs have been reported to induce this disorder. We describe the first reported patient who developed LABD after ingestion of the non‐steroidal anti‐inflammatory agent (NSAID) piroxicam.
The efficacy of a new topical treatment for psoriasis: Mirak
Authors: Seyger M.M.B. , van de Kerkhof P.C.M. , van Vlijmen‐Willems I.M.J.J. , de Bakker E.S.M. , Zwiers F. , de Jong E.M.G.J. 
Published: September 2006

AbstractBackground A new natural product for the treatment of psoriasis has recently become available in many European countries: Mirak. The Mirak Home Care Packs consist of natural spring water, volcanic earth and vitamin E cream. Recently, the efficacy of Mirak has come into question. As this treatment is used by many psoriasis patients in Europe, it is important for dermatologists to be informed about the clinical effects of the therapy.Aim To evaluate the efficacy and side effects of the Mirak Home Care Packs.Methods By means of a placebo‐controlled left/right comparison, both clinical and histological parameters were evaluated during 6 weeks of treatment.Results The reduction in induration was significantly greater in the Mirak‐treated lesions than in the lesions treated with a placebo. A reduction in desquamation was found in both treatments; the difference between the treatments was not statistically significant. A decrease in number of proliferative cells in the Mirak‐treated lesions was seen, but the difference with placebo‐treated lesions was not significant. The other investigated parameters did not change during treatment. No side effects were seen.Conclusions The Mirak Home Care Pack induces a modest therapeutic effect compared to placebo treatment, without significant side effects. Treatment with the Mirak Home Care Packs alone will probably not be able to compete with the already existing treatments for psoriasis.
Multinucleate cell angiohistiocytoma: a report of two cases
Authors: Aloi F. , Solaroli C. , Tomasini C. , Pippione M. 
Published: September 2006

AbstractWe report the clinical, histological and immunological features of two cases of multinucleate cell angiohistiocytoma (MCAH) in women of 32 and 53 years of age, respectively. Clinically, MCAH occurs mostly in middle‐aged women and consists of crops of reddish‐purple, dome‐shaped papules especially on the limbs. Histologically, the reticular dermis presents an increased number of small vascular channels with plump endothelial cells embedded in a fibrohistiocitic stroma with numerous bizarre multinucleate cells. Bizarre multinucleated cells are not specific to MCAH; they can be observed in numerous other cutaneous conditions. However, MCAH presents quite distinctive clinico‐pathological findings and may be easily differentiated from other cutaneous disorders.
Disseminated papular acantholytic dyskeratosis
Authors: Ciupinska Magdalena , Kalbarczyk Kazimierz , Jablonska Stefania 
Published: September 2006

AbstractWe present two cases of elderly women with clinically atypical transient disseminated papular eruption, showing suprabasal epidermal clefts with dyskeratosis and acantholysis. The clinical picture did not correspond to either Darier's disease, Hailey's disease or Graver's acantholysis. In spite of clinical similarity the cases differed in course and outcome. Overlapping dyskeratosis and acantholysis varied in different specimens. The case with transient acantholytic lesions of short duration showed much more pronounced dyskeratosis than the other in which several relapses occurred in a 4‐year period. Such cases defying classification belong to the heterogeneous group of papular acantholytic dyskeratosis. (c) 1998 Elsevier Science B.V. All rights reserved
Allergic contact dermatitis from naftifine in a child without cross‐reaction to terbinafine
Authors: Goday J.J. , González‐Güemes M. , Yanguas I. , Ilardia R. , Soloeta R. 
Published: September 2006

AbstractAllergic contact dermatitis from naftifine has been scarcely described in the English literature, all of them in adults. We report a case of a 12‐year‐old girl who developed an acute eczema on her neck after application of a naftifine cream. This fact was confirmed by a patch‐test study. We did not find a cross‐reaction to terbinafine, a structurally linked allylamine.
Cellulitis of the eyelids associated with sinusitis and brain abscess
Authors: Shinagawa Yumiko , Ando Iwao , Kukita Atsushi , Kitazawa Eriko , Saruki Kiyofumi , Aoki Makoto 
Published: September 2006

AbstractErythema in the orbital area can indicate systemic and life‐threatening diseases. We experienced an unusual and serious case of orbital cellulitis that was difficult to distinguish from a case with good prognosis. A 21‐year‐old man developed an erythema around his eyes. He exhibited no symptoms that would suggest lesions in deep tissues, but his condition turned out to be cellulitis retrogradely metastasized from an odontogenic sinusitis traced to a dental treatment problem. Computed tomography revealed complication of a large abscess in the frontal lobe. Cellulitis of the orbital area requires particular clinical discretion.
Amelanotic lentigo maligna and amelanotic lentigo maligna melanoma: a report of three cases mimicking intraepidermal squamous carcinoma
Authors: Allan S. J.R. , Dicker A.J. , Tidman M.J. , McLaren K.M. , Hunter J.A.A. 
Published: September 2006

AbstractThe clinical diagnosis of amelanotic melanoma may pose diagnostic difficulties. We report three cases of amelanotic lentigo maligna, two of which developed an invasive component (lentigo maligna melanoma). The clinical appearances in each case mimicked intraepidermal squamous carcinoma.
Efficacy and safety of mizolastine 10 mg in a placebo‐controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR study1
Authors: Dubertret L. , Aguttes M. Murrieta , Tonet J. 
Published: September 2006

AbstractBackgroundMizolastine is a novel histamine H1‐antagonist registered in Europe for the management of allergic rhinitis and urticaria.ObjectivesTo compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria (CIU).MethodsA multicentre, double‐blind, parallel group study was designed in which 247 patients with CIU were randomised after a 1‐week placebo run‐in period to 10 mg daily mizolastine (n= 88), 10 mg daily loratadine (n= 79), or placebo (n= 80) for a 4‐week treatment period.ResultsMizolastine and loratadine both relieved symptoms of CIU. After 2 weeks' treatment, the severity of pruritus (visual analogue score (VAS) assessed by patients) decreased significantly in both the mizolastine and loratadine groups compared with placebo (mizolastine: –36.7 mm, P= 0.0001; loratadine: –29.8, P= 0.0071; placebo: –16.3); this improvement with both active treatments was maintained throughout the treatment period, the difference being significant only for the mizolastine group (P= 0.0090). Both active treatments were also associated with reduced weekly episodes of urticaria compared with placebo, which was significant after 2 weeks' treatment (mizolastine: 7.9 episodes, P= 0.0061; loratadine: 8.3, P= 0.0221; placebo: 13.3). Angioedema was improved to a clinically significant extent with mizolastine, and loratadine compared with placebo in those patients who had this symptom before treatment Overall tolerability of both treatments was similar to placebo, and there were no clinically relevant effects on cardiac repolarisation with either mizolastine or loratadine.ConclusionMizolastine (10 mg daily) is confirmed as an effective and well tolerated agent, comparable to loratadine and superior to placebo, for the management of CIU. Mizolastine acted as rapidly as loratadine in improving urticarial symptoms from the first day of treatment.
Immunomodulators in the treatment of cutaneous lymphoma
Authors: Rogalski Christina , Dummer Reinhard , Burg Günter 
Published: September 2006

AbstractBackgroundCutaneous lymphoma involves clonal proliferation of immunocompetent cells. Immunointerventional strategies are a rational approach to the treatment of cutaneous lymphoma given the pathophysiological aspects of the disease.ObjectiveImmunomodulatory therapies in cutaneous lymphoma are reviewed, including interferons, interleukin‐2, cyclosporin A, monoclonal antibodies, autologous bone marrow transplantation, fusion toxins, thymopentin and extracorporeal photopheresis as well as recently reported methods such as vaccination therapy, mycophenolate, and new retinoids.Results/ConclusionCutaneous lymphoma is sensitive to immunointerventions. This approach should be used in early stages of the disease when it is more susceptible and benefits better from immunomodulatory treatment modalities.